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Background: Peripartum cardiomyopathy (PPCM), a diagnosis of exclusion, is identified with the presen-
tation of heart failure (HF) secondary to left ventricular (LV) systolic dysfunction without any other 
cause of HF recognized in the last month of pregnancy or within first five months after delivery, abortion, 
or miscarriage. It is a life-threatening condition that is frequently underdiagnosed and inadequately 
treated, whereas the morbidity and mortality rates range between 7% and 50%. Therefore, it is necessary 
to report the case related to this condition.
Objective: This case report aims to describe the importance of early diagnosis and treatment in PPCM
Case Illustration: A 34-year-old woman was referred to RSSA with worsening shortness of breath (SOB). 
She has given birth approximately 2.5 months before admission. History taking, clinical and ancillary 
findings revealed the diagnosis of PPCM. She was treated with a diuretic, aldosterone antagonist, ACE-I, 
beta-blocker, anticoagulant, and bromocriptine. The symptoms were improved in the following days. 
The patient was discharged in good condition and educated to comply with her medications.
Conclusion: Swift clinical judgment and related objective examinations are compulsory to establish a 
diagnosis and benefit the patient.
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 PPCM is defined as idiopathic cardiomyopathy developing in 
the last month of pregnancy or within the first five months after 
delivery, abortion, or miscarriage. It should be under the condition that 
no other causes for heart failure are identified, with a left ventricular 
(LV) ejection fraction (EF) <45%.1,2 There are several predisposing 
factors of PPCM including multiparity and multiple pregnancies, 
ethnicity, older age of mother, pre-eclampsia, extended utilization of 
tocolytic beta-agonists, smoking, diabetes, hypertension, malnutrition, 
and family history.1-3
 Diagnosis establishment of PPCM obligates supporting 
echocardiographic findings of left ventricular dysfunction with LVEF 
<45% and oftentimes left ventricular dilatation in the absence of an 
alternative explanation, though the later is not always present. Other 
findings in echocardiography may also include left atrial or biatrial 
enlargement, right ventricular dilatation and dysfunction, pulmonary 
hypertension, functional mitral and tricuspid regurgitation, and 
intracardiac thrombus. 2,3,7
 A patient with PPCM was reported in this case. She has 
suffered from shortness of breath (SOB) while doing heavy activities 
since 2.5 months ago. She did not take any medical care. Because of 
worsening SOB, she brought to RSSA and diagnosed with PPCM. Her 
condition improved during care and discharged with appropriate 
condition. 
2. Case Illustration
 A 35-year-old primiparous woman referred to RSSA with 
aggravating SOB at rest since a day before admission. The SOB was 
followed by palpitation, cold sweating, and leg swelling. She 
complained that the SOB became worse in the last seven days. There 
were not any chest pain nor syncope. Antenatal care was routinely 
performed at the midwife. There was no history of hypertension before 
pregnancy, diabetes, heart disease, nor a family history of heart 
disease. The patient was obese, but she did not have a serious condition 
before admission. In the last month of pregnancy, a pre-eclampsia was 
developing. She gave birth through cesarean section 2.5 months ago 
due to pre-eclampsia. History of dyspnea on effort (DOE) while doing 
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moderate to heavy activities, orthopnea (OE), and paroxysmal noctur-
nal dyspnea (PND) were found since two months ago. She did not ever 
seek any medical consultation at that time.
 Physical examination revealed compos-mentis, blood 
pressure (BP) 130/85 mmHg, heart rate (HR) 125 beats per minute 
(bpm), respiration rate (RR) 24 times per minute (tpm), temperature 
(T) 36.3 °C, and saturation (SpO2) 99% on oxygen (O)2 nasal cannula 
(NC) 4 litre per minute (lpm). Anaemia was not found. Jugular venous 
pressure (JVP) was R + 5 cmH20. There were heart enlargement 
findings on auscultation with palpable apex cordis at Intercostalis (ICS) 
VI midclavicular (MCL) sinistra and found systolic murmur grade III/VI 
at the apex. There was also rales on the mediobasal bilateral lung.
 White cell blood count was 10100/μL, Hb 10.3 g/dl, C 
reactive protein (CRP) 6.8 mg/dl (normal value < 0.3), Nt pro BNP 
3164 pg/ml (normal value < 100 pg/ml). The electrocardiography 
(ECG) examination result showed sinus tachycardia with poor R wave 
progression, as seen in Figure 1. Chest x-ray (CXR) examination 
revealed cardiomegaly with congestive pulmonum (Figure 2). Echocar-
diography findings showed the presence of a reduced ejection fraction 
of left ventricular systolic function (EF 38%), fractional shortening (FS) 
of 11% along with mild mitral regurgitation and mild tricuspidal 
regurgitation. Left atrial and ventricle appeared enlarged and diffusely 
hypokinetic. End-diastolic volume of the left ventricle was 103 ml/m2 
and end-diastolic dimension 5.0 cm with an end-diastolic dimension 
index of 2.9 cm/m2.
 The patient was diagnosed with moderate PPCM. She was 
medicated with loop diuretic therapy intravenously with adjusting dose 
according to congestion state, angiotensin-converting enzyme inhibitor 
(ACE-i), mineralocorticoid receptor antagonist (MRA) agent, and 
bromocriptine. Then, after congestion was improved, beta-blocker was 
initiated. In the following days, she received optimization of heart 
failure treatment. She routinely took controlled medication. After six 
months of medication, echocardiography examination was performed 
and showed the recovery of LV function.  
3. Discussion
 PPCM typically manifests itself as heart failure in the last 
month of pregnancy or several months after delivery or abortion where 
other underlying factors of heart failure is not identified. The condition 
is potentially fatal. The cause is largely not comprehended although it 
is often linked to various risk factors, such as multiparities, pre-eclamp-
sia, maternal age ≥30 years old, and black race [6,11,12]. As found in 
this patient, a history of pre-eclampsia and older maternal age were 
found.
 PPCM is frequently missed because of the prominent 
symptom, dyspnea, which is a common complaint in normal pregnancy, 
particularly when the patient does not fit the typical epidemiology 
[6,13]. According to this case, the patient had suffered from intermit-
tent DOE, PND, OE, leg swelling, and palpitation ten days after the 
labour. Because there is no marked limitation on her daily activities, she 
did not seek any medical help. About two months later, the symptoms 
became worsen. It was accompanied by palpitation and leg swelling. 
Because of worsening symptoms, she was brought to the hospital and 
referred to RSSA. She was diagnosed with PPCM. Physical examination 
supported to history taking of the patient, including tachycardia, 
tachypnea, increased JVP, basal bilateral rales from lung auscultation, 
and shifted apex palpable at ICS VI MCL confirming the cardiomegaly, 
and leg swelling. Other supporting findings of PPCM in this patient 
were increased NT-pro BNP, cardiomegaly and congestive pulmonum 
from CXR, and systolic dysfunction of LV with decreased fractional 
shortening found from echocardiography. The course of symptoms and 
supporting patient findings were correlated with a diagnostic pathway 
in patients with moderate PPCM (Figure 2).6,9.12
 The treatment adheres to the standard protocols for other 
types of systolic HF. Although the therapeutic plans for heart failure are 
well-entrenched, antepartum prescriptions need adjustments to avoid 
fetal toxicity. Moreover, the implications of breastfeeding infants also 
should be considered. The aims are to improve the hemodynamic 
status, minimize HF symptoms, and optimize long-term outcomes. 9,12,13 
Related to this patient, she received intravenously diuretic during the 
first day of care until the congestion improving. She also got additional 
bromocriptine. According to the guideline, the BOARD regiment was 
given to this patient, including bromocriptine, oral HF drugs, anticoag-
ulant, vasodilators, and diuretic agents. The role of these regiments was 
discussed in the following paragraphs.
 Diuretics are useful to decrease the preload and relieve 
pulmonary congestion or peripheral oedema. Some of the most 
frequently-used diuretics such as furosemide and hydrochlorothiazide, 
are generally safe during pregnancy and subsequent lactation. The 
patient received furosemide to decongest the congestion state. Spirono-
lactone, a potassium-sparing diuretic, has been used as one of heart 
failure treatment; however, the lack of sufficient data regarding its 
appliance in pregnancy urge for cautious use in that condition. Other 
drugs categories are contraindicated during pregnancy because of its 
teratogenic effect, such as angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers. Beta-blockers, administered along 
with ACE inhibitors, are the first-line heart failure option, reducing 
mortality through modulation of neurohormonal activation. To 
optimize heart failure therapy in this patient, she received those 
regiments, including MRA, ACE inhibitor, and beta-blocker agents 6,9,12. 
 Based on the aforementioned pathophysiological process of 
16kD-prolactin-mediated PPCM and supported by randomized studies, 
the addition of bromocriptine, a prolactin-blocker, to the standard 
regiment of heart failure treatment exerts favourable effect on LVEF 
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Figure 1. Thoraxic X-ray showed cardiomegaly with congestive 
pulmonumdeviation and T waves inversion in precordial leads 
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and mortality rate in severe acute PPCM cases. However, it is important 
to note that bromocriptine will effectively disrupt lactation and necessi-
tate a discussion with the mother if this option is needed. Nonetheless, 
the evidence for bromocriptine efficacy in PPCM was derived from 
relatively small studies with many confounding variables. More data 
and better insight on the role of bromocriptine in PPCM may be provid-
ed from the on-going EURObservational Programme.9,12,13 Anticoagu-
lant is endorsed by the American Heart Association if EF < 30% during 
late pregnancy and up to 8 weeks post-partum. If bromocriptine is used, 
therapeutic anticoagulation should be considered.12, 14 Class recommen-
dation of bromocriptine administration along with prophylactic (thera-
peutic) anticoagulation is IIa C.15 Even though bromocriptine and 
anticoagulant agents, are included in the class IIa C recommendation 
from the guideline, she still received those regiments because of PPCM 
condition. 
 According to this case, the symptoms were improved in the 
following days with those regiments. She was discharged with the 
appropriate condition. PPCM patients and their partners should be 
carefully counselled and informed (class I recommendation) regarding 
the longer-term prognosis. In the patient with PPCM, subsequent 
pregnancy is not recommended if LVEF does not normalize (class III C 
recommendation). Information Education Communication (IEC) was 
given to the patient, including consuming a low-salt diet, eating a 
well-balanced diet, taking medicine, and controlling the doctor regular-
ly.
 A 6-month visit with echocardiography examination in PPCM 
is needed until the LV function is recovered to an LVEF >50%. In 
women with LV recovery who remain stable after tapering of heart 
failure drug therapy, an annual visit is recommended for up to 10 years. 
There is no consensus about whether heart failure medication can be 
stopped in women with a recovered LV function or subclinical dysfunc-
tion. Some of the PPCM Study Group members recommend life-long 
heart failure therapy at the highest tolerated dose based on the fact that 
deterioration of LV function has been observed in women with normal-
ized cardiac function. If patients display incomplete recovery signs 
despite recovered LVEF such as persistent LV dilatation or reduced 
myocardial strain, a continuation of heart failure drugs (ACE inhibitor, 
beta-blocker, MRA) should be considered. IEC was important to PPCM 
patient making good adherence and improving the survival rate 
subsequently.12,14,15
4. Conclusion
 We reported a case of a 34-year-old woman with moderate 
PPCM presentation. She received BOARD regiments treatment. The 
symptoms were improved the following day. She was discharged in 
good condition. She was advised to take regular control and consume 
the medication routinely. Echocardiography follows up in the sixth 
month after hospital discharge was advised to evaluate the LV function 
and direct future therapy. 
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Figure 2. Diagnostic pathway in patients with suspected peripartum cardiomyopathy (PPCM). BNP, 
B-type natriuretic peptide; ECG, electrocardiogram; HF, heart failure; LVEF, left ventricular ejection 
fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricular.1
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